Oral versus intravenous chemotherapy for HER2-negative metastatic breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial compares a new oral (pill) form of the chemotherapy drug paclitaxel with the standard intravenous (IV) version for people with HER2-negative metastatic breast cancer. The oral form is combined with another drug to help the body absorb more of the chemotherapy, which may make it easier and more convenient while being just as effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have HER2-negative breast cancer that has spread to other parts of the body
- Your doctor has recommended paclitaxel chemotherapy as a single treatment
- You have at least one tumor that can be measured on a CT scan
- You have adequate blood cell counts, liver function, and kidney function
- You are able to take oral medications and have no major stomach or bowel issues
- You have not had a severe allergic reaction to paclitaxel or to contrast dye used in scans
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests how food affects the absorption of an oral form of paclitaxel (a chemotherapy drug) when taken with another drug called encequidar. It's for people with advanced solid tumors who have limited treatment options.
This trial tests if taking oral chemotherapy pills with trastuzumab (Herceptin) works as well as IV chemo (paclitaxel) with Herceptin after surgery for HER2-positive, lymph node-negative early breast cancer. It aims to find a more convenient treatment option.
This trial tests a combination of low-dose oral paclitaxel (a chemotherapy pill taken regularly) plus immunotherapy to treat advanced breast cancer that doesn't have high levels of HER2 protein. The goal is to slow or shrink tumors while managing side effects better than traditional high-dose chemotherapy.
This trial compares two different chemotherapy combinations (one with a newer type of paclitaxel called polymeric micelles, plus an immunotherapy drug called adebelimab) against a standard taxane plus HP regimen, as first-line treatment for advanced HER2-positive breast cancer. The goal is to see if the new combination works better at controlling the cancer.
This trial tests an oral form of paclitaxel combined with standard HER2 therapy given before surgery for HER2-positive breast cancer. It aims to find the best dose and see how well it works.
This trial tests a treatment for HER2-positive breast cancer given without intravenous (IV) therapy - likely as injections under the skin. It aims to see if this approach is effective before surgery.
Hear when a new Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.